The lung cancer screening market is experiencing significant growth as healthcare systems shift toward early detection strategies. Screening methods—such as low-dose CT (LDCT), chest X-rays, and liquid biopsies—are increasingly used to identify lung cancer at treatable stages. Key drivers include rising lung cancer incidence, especially among smokers, technological innovations (including AI-enhanced imaging and minimally invasive diagnostics), and enhanced public awareness. While the market faces challenges like high equipment costs and limited access in some regions, improved reimbursement policies, awareness programs, and emerging technologies are expanding reach. As early detection becomes standard in high-risk populations, the lung cancer screening market is poised for sustained global growth.
According to Fortune Business Insights, the global lung cancer screening market was valued at USD 3.28 billion in 2023. The market is projected to grow from USD 3.55 billion in 2024 to USD 7.10 billion by 2032, exhibiting a CAGR of 9.1% during the forecast period. In 2023, North America dominated the lung cancer screening market with a market share of 54.27%.
In January 2024, Nova Scotia launched a new lung cancer screening program targeting high-risk individuals—a significant public health milestone that underscores the push for nationwide early detection strategies.